These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1129 related items for PubMed ID: 20823238

  • 1. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
    Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.
    Proc Natl Acad Sci U S A; 2010 Sep 28; 107(39):16759-65. PubMed ID: 20823238
    [Abstract] [Full Text] [Related]

  • 2. Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.
    Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP.
    Clin Cancer Res; 2014 Mar 15; 20(6):1590-600. PubMed ID: 24449822
    [Abstract] [Full Text] [Related]

  • 3. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells.
    Krause WC, Shafi AA, Nakka M, Weigel NL.
    Int J Biochem Cell Biol; 2014 Sep 15; 54():49-59. PubMed ID: 25008967
    [Abstract] [Full Text] [Related]

  • 4. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.
    Cancer Res; 2012 Jul 15; 72(14):3457-62. PubMed ID: 22710436
    [Abstract] [Full Text] [Related]

  • 5. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO, Fahrenholtz CD, Burnstein KL.
    Mol Endocrinol; 2012 Dec 15; 26(12):1967-79. PubMed ID: 23023561
    [Abstract] [Full Text] [Related]

  • 6. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
    Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.
    Prostate; 2016 Dec 15; 76(16):1536-1545. PubMed ID: 27473672
    [Abstract] [Full Text] [Related]

  • 7. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
    Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y.
    Cancer Res; 2009 Mar 15; 69(6):2305-13. PubMed ID: 19244107
    [Abstract] [Full Text] [Related]

  • 8. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
    Yamashita S, Lai KP, Chuang KL, Xu D, Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, Yeh S, Chang C.
    Neoplasia; 2012 Jan 15; 14(1):74-83. PubMed ID: 22355276
    [Abstract] [Full Text] [Related]

  • 9. Melatonin Inhibits Androgen Receptor Splice Variant-7 (AR-V7)-Induced Nuclear Factor-Kappa B (NF-κB) Activation and NF-κB Activator-Induced AR-V7 Expression in Prostate Cancer Cells: Potential Implications for the Use of Melatonin in Castration-Resistant Prostate Cancer (CRPC) Therapy.
    Liu VWS, Yau WL, Tam CW, Yao KM, Shiu SYW.
    Int J Mol Sci; 2017 May 31; 18(6):. PubMed ID: 28561752
    [Abstract] [Full Text] [Related]

  • 10. AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.
    Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM.
    Oncogene; 2012 Nov 08; 31(45):4759-67. PubMed ID: 22266865
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
    Antonarakis ES, Armstrong AJ, Dehm SM, Luo J.
    Prostate Cancer Prostatic Dis; 2016 Sep 08; 19(3):231-41. PubMed ID: 27184811
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Methylselenol prodrug enhances MDV3100 efficacy for treatment of castration-resistant prostate cancer.
    Zhan Y, Cao B, Qi Y, Liu S, Zhang Q, Zhou W, Xu D, Lu H, Sartor O, Kong W, Zhang H, Dong Y.
    Int J Cancer; 2013 Nov 08; 133(9):2225-33. PubMed ID: 23575870
    [Abstract] [Full Text] [Related]

  • 15. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
    Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS.
    PLoS One; 2014 Nov 08; 9(10):e111545. PubMed ID: 25356728
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.
    Cao B, Qi Y, Zhang G, Xu D, Zhan Y, Alvarez X, Guo Z, Fu X, Plymate SR, Sartor O, Zhang H, Dong Y.
    Oncotarget; 2014 Mar 30; 5(6):1646-56. PubMed ID: 24722067
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM.
    Cancer Res; 2013 Jan 15; 73(2):483-9. PubMed ID: 23117885
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.